Protagonist Therapeutics (PTGX) – Research Analysts’ Recent Ratings Changes

Protagonist Therapeutics (NASDAQ: PTGX) has recently received a number of price target changes and ratings updates:

• 8/17/2026 – Protagonist Therapeutics had its price target raised by BMO Capital Markets from $112.00 to $178.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Protagonist Therapeutics was upgraded by Weiss Ratings from “sell (d+)” to “hold (c+)”.
• 8/10/2026 – Protagonist Therapeutics had its price target raised by Truist Financial Corporation from $145.00 to $170.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Protagonist Therapeutics had its price target raised by Wedbush from $118.00 to $173.00. They now have an “outperform” rating on the stock.
• 8/10/2026 – Protagonist Therapeutics was upgraded by UBS Group AG to “buy”.
• 8/10/2026 – Protagonist Therapeutics was upgraded by The Goldman Sachs Group, Inc. from “neutral” to “buy”. They now have a $186.00 price target on the stock, up from $110.00.
• 8/8/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Protagonist Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/6/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $151.00 to $153.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Protagonist Therapeutics had its price target raised by Citigroup Inc. from $130.00 to $175.00. They now have a “buy” rating on the stock.
• 7/25/2026 – Protagonist Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/17/2026 – Protagonist Therapeutics was given a new $165.00 price target by Johnson Rice.
• 7/17/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $119.00 to $151.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Protagonist Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/7/2026 – Protagonist Therapeutics had its price target raised by Truist Financial Corporation from $121.00 to $145.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Protagonist Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 6/27/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insider Transactions at Protagonist Therapeutics

In other news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $149.11, for a total value of $9,805,622.71. Following the sale, the chief executive officer owned 523,478 shares in the company, valued at $78,055,804.58. This represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 127,000 shares of company stock worth $17,818,139. 5.19% of the stock is owned by insiders.

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.